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Objective: Endovascular aneurysm repair (EVAR) is associated with signiﬁcant direct device costs. Such costs place EVAR
at odds with efforts to constrain healthcare expenditures. This study examines the procedure-associated costs and
operating margins associated with EVAR at a tertiary care academic medical center.
Methods: All infrarenal EVARs performed from April 2011 to March 2012 were identiﬁed (n[ 127). Among this cohort,
49 patients met standard commercial instruction for use guidelines, were treated using a single manufacturer device, and
billed to Medicare diagnosis-related group (DRG) 238. Of these 49 patients, net technical operating margins (technical
revenue minus technical cost) were calculated in conjunction with the hospital ﬁnance department. EVAR implant costs
were determined for each procedure. DRG 238-associated costs and length of stay were benchmarked against other
academic medical centers using University Health System Consortium 2012 data.
Results: Among the studied EVAR cohort (age 75, 82% male, mean length of stay, 1.7 days), mean technical costs totaled
$31,672. Graft implants accounted for 52% of the allocated technical costs. Institutional overhead was 17% ($5495) of
total technical costs. Net mean total technical EVAR-associated operating margins were L$4015 per procedure. Our
institutional costs and length of stay, when benchmarked against comparable centers, remained in the lowest quartile
nationally using University Health System Consortium costs for DRG 238. Stent graft price did not correlate with total
EVAR market share.
Conclusions: EVAR is currently associated with signiﬁcant negative operating margins among Medicare beneﬁciaries.
Currently, device costs account for over 50% of EVAR-associated technical costs and did not impact EVAR market share,
reﬂecting an unawareness of cost differential among surgeons. These data indicate that EVAR must undergo dramatic
care delivery redesign for this practice to remain sustainable. (J Vasc Surg 2014;59:283-90.)The advent and subsequent evolution of endovascular
aneurysm repair (EVAR) has altered not only both the
morbidity and mortality proﬁle of abdominal aortic aneu-
rysm (AAA) repair but also the manner in which aneurysm
care is delivered.1-3 Accordingly, EVAR has solidiﬁed its
role in contemporary practice as a mainstay of therapy for
both elective and ruptured AAA, in anatomically suited
patients. Despite these tangible gains in patient care,
EVAR remains associated with signiﬁcant procedure-
related costs.4,5
Healthcare costs have steadily increased over time with
some projections anticipating expenditures to reach 20%
of U.S. gross domestic product by 2020.6 As a result,the Section of Vascular Surgery, Dartmouth-Hitchcock Medical Cen-
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with a growing emphasis placed on value, quality, and cost.
While EVAR represents an appealing prevalent less invasive
procedure in contemporary practice, its high cost proﬁle
decreases its potential value, placing it at odds with poten-
tial looming cost constraint reforms. The purpose of this
study was to examine the procedure-associated costs and
operating margins associated with EVAR at a tertiary care
academic medical center.
METHODS
Subjects. This study reﬂects data collected at
Dartmouth-Hitchcock Medical Center on all patients
who underwent elective EVAR between April 2011 and
March 2012 (n ¼ 127). Ruptured aneurysms were
excluded. We sought to derive a relatively uniform
anatomic operative cohort for cost analysis, in whom any
commercially available device could be used. We, thus,
excluded cases where anatomy was deemed outside
conventional instruction for use guidelines. We next
included cases treated only by a single vendor’s device,
thereby eliminating cases treated with multiple pieces from
various manufacturers, or those with multiple extensions or
cuff placements that would confound cost analysis. We
lastly restricted our payer source to Medicare remunerated
cases, which constitute 88% of our aneurysm practice,
whose procedures were billed using the diagnosis-related
group (DRG) 238 code, reaching a ﬁnal patient cohort283
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Fig 1. University Health System Consortium (UHC) 2012 diagnosis-related group (DRG) 238 overall costs stratiﬁed
by center. Dartmouth-Hitchcock Medical Center (DHMC) is in the lowest quartile of reporting centers (arrow). Data
reﬂect all DRG 238 procedures.
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major complications were also excluded from further cost
analysis for this study. Exclusion criteria are further detailed
in the Supplementary Table (online only). All patients were
treated with commercially available stent graft devices
determined by the operating surgeon.
Outcomes and variable deﬁnitions. Hospital ﬁnan-
cial cost and revenue data was obtained from the
Dartmouth-Hitchcock Department of Finance and adju-
dicated by the institution’s Chief Financial Ofﬁcer. Annual
net technical operating margin for DRG 238 was deter-
mined for the Section of Vascular Surgery. Overall, DRG
238 costs and length of stay were further benchmarked
against comparable academic medical centers using
University Health System Consortium (UHC) 2012 cost
data to better deﬁne our institution’s cost proﬁle in relation
to comparable institutions. DRG reimbursement reﬂects
a variety of institution-associated factors including
geographic location, teaching status, base payment, and
relative weight. At our institution, EVAR constituted 42%
of the DRG 238 remunerated cases. Furthermore, cost to
charge ratios can be used to compare cost across institu-
tions relative with charges. This methodology has been
previously described in further detail for similar analyses.4
Our cost methodology did not use hospital based charges
in its computation. DRG 238 technical costs and associated
revenues were determined for the study cost cohort (n ¼
49) to determine per case costs and margins. EVAR stent
graft implant costs were determined. Additional technical
institutional cost components and expense breakdown
included operating room (OR), supplies, which included
the expense of additional stents, wires, catheters, instru-
ments, and other adjunctive equipment, not including the
stent graft implantable, bed, which included room expenses
including ﬂoor, telemetry, and/or intensive care unit costs.
Radiology expenses included any plain ﬁlms, ultrasound,computed tomography scans and additional diagnostic
testing. Laboratory and pharmacy charges were grouped,
as done in previous published analyses. Finally, other
constituted overall miscellaneous-associated costs including
institutional overhead, which was allocated based on a local
varying formula by category. OR costs are allocated by time
in our institution and included costs of OR staff, depreci-
ation of equipment, anesthesia time, and recovery room.
Thus, the cost methodology at Dartmouth-Hitchcock
Medical Center is unique and not necessarily applicable
to other institutions. Net technical operating margins
(technical revenues minus technical costs) were calculated.
Market share and device costs were also determined for
major commercial vendors. Shifts in market share, among
the entire EVAR cohort (n ¼ 127) were projected using
current graft costs to guide device selection for the esti-
mated 44% of our total aneurysm practice in whom
anatomy would permit use of any major commercially
available device, thus, permitting hypothetical interchange
of speciﬁc stent grafts. Projected savings were then deter-
mined based on the graft cost disparity and subsequent
shifts in market share in this subset (44%) of patients
from the entire EVAR cohort (n ¼ 127).
RESULTS
Over the study interval, a total of 127 patients under-
went elective EVAR, in whom 49 met inclusion criteria
for cost analysis. Mean length of stay for this group (n ¼
49) was 1.7 days. The net annual operating margin for
all DRG 238 remunerated EVAR was substantially nega-
tive, approaching e$500,000.00 per year.
To better account for this negative margin ﬁnding,
hospital DRG 238 overall costs and DRG 238 length of
stay, two major drivers for procedure-associated costs,
were benchmarked against comparable academic medical
centers using UHC 2012 data. Our institution compared
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Fig 3. Diagnosis-related group (DRG) 238 remunerated endovascular aneurysm repair (EVAR) technical costs,
revenues, and operating margin per EVAR case demonstrating a negative e$4015 margin.
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Fig 2. University Health System Consortium (UHC) 2012 diagnosis-related group (DRG) 238 length of stay
stratiﬁed by center. Dartmouth-Hitchcock Medical Center (DHMC) remains in the lowest quartile among centers
(arrow). Data reﬂect all DRG 238 procedures.
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participating institutions (Figs 1 and 2).
On a per case level, reﬂecting the study cohort for cost
analysis (n ¼ 49), DRG 238 mean technical costs
($31,672) surpassed DRG 238 mean technical revenue
($27,657), resulting in a negative technical margin
of $4,015 per case, consistent with the cumulative annual
net operating margin ﬁnding (Fig 3). Stent graft implants
accounted for the majority of technical cost (52%). Among
the nongraft implant drivers for technical cost, OR (17%)
was the largest. Additional costs included supplies (8%),
bed (7%), radiology (2%), laboratory and pharmacy (2%),
and other (12%, institutional overhead costs). Comparedwith nonimplant costs, stent grafts still accounted for
greater than threefold more in technical costs than OR
costs (Fig 4). Furthermore, while associated stent graft
costs were determined to account for 52% of the per case
technical costs, they assumed a greater percentage (60%),
of the DRG payment, thus contributing to the aforemen-
tioned negative annual operating margin.
Given the substantial cost of graft implants to the
procedure cost burden, total vendor market share was
determined for the entire Section of Vascular Surgery,
reﬂecting the entire EVAR cohort (n ¼ 127). Market share
and graft cost did not correlate, with higher cost devices
assuming greater utilization, while the lower cost devices
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Fig 4. Nonstent graft overhead costs associated with diagnosis-
related group (DRG) 238 remunerated endovascular aneurysm
repair (EVAR). By comparison, stent grafts (shown on left)
account for threefold more than operating room (OR) costs, the
greatest nonimplant hospital costs.
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were next projected using current device costs and 44% of
the total EVAR volume in which we estimate that all major
commercially available devices could be used interchange-
ably with equipoise. Accordingly, vendor A would increase
its market share from 12% to 51%, whereas vendor D
would experience a reduction in market share from 54%
to 30% (Fig 6). Projected savings related to market share
shifts would approach $200,000 annually, reﬂecting the
cost disparity among devices for the 44% subset of patients
in whom device interchange was permissible.
DISCUSSION
The inexorable rise in healthcare expenditures has
ushered in a new era of care delivery with a growing
emphasis placed on cost reduction, quality improvement,
and overall value.6 In this context, while the Affordable
Care Act has provided de facto expansion in healthcare
access to many Americans, it remains unclear whether it
will effectively constrain the associated costs of care
delivery. Accordingly, healthcare systems and hospitals
alike are now confronted with growing costs associated
with expensive specialty care, which have signiﬁcant
sustainability implications. EVAR has emerged as a poten-
tial high value procedure in contemporary practice, though
it remains associated with signiﬁcant procedure-associated
costs.4,5,7-9 Accordingly, this study aimed to examine the
procedure-associated costs and revenues associated with
Medicare remunerated EVAR. Medicare currently consti-
tutes 88% of our total EVAR practice, thus highlighting
the signiﬁcance of delivering EVAR to this substantial
and likely growing segment of the patient population.
This study provides important insight surrounding the
ﬁnancial proﬁle of EVAR in contemporary practice. Specif-
ically, EVAR was associated with negative technical oper-
ating margins both annually and on a per case basis when
associated with a Medicare payer source. In keeping with
other studies, which have previously demonstrated the
signiﬁcant expense proﬁle of EVAR,4,5,7-10 this study docu-
mented that stent grafts serve as the major technical cost
driver, constituting over 50% of the associated costs.Furthermore, compared with other nongraft procedure
costs, stent grafts were notably more than threefold greater
than any of the nonimplant hospital-associated costs.
Though EVAR stent grafts accounted for the majority
of technical costs, our analysis also attempted to deﬁne
additional opportunities for comprehensive procedure-
associated cost reduction and quality improvement, to
further eliminate procedure-associated waste, though these
costs were not the primary focus of this report.
This analysis is in keeping with additional studies that
determined the disproportionate costs associated with the
requisite stent grafts for EVAR in comparison to the proce-
dure speciﬁc DRG Medicare reimbursement rates. Speciﬁ-
cally, Sternbergh et al, in a multicenter study surrounding
EVAR-associated costs, determined that Medicare pay-
ments in 1999 were insufﬁcient to cover the associated
costs of the procedure at that time, resulting in a negative
margin.5 Moreover, an analysis of EVAR-associated costs
by Bertges et al, also demonstrated similar ﬁndings in
2003. In their study, when hospital reimbursement was
weighted by DRG case mix, there was an average shortfall
of $2162 and $3827, respectively, depending on the reim-
bursement methodology used.4 Interestingly, this study
also demonstrates a sustained negative procedure-
associated margin for EVAR. Furthermore, it appears this
is largely driven by high device-associated costs, which
have increased over time, like many costs. Despite these
ﬁndings, both past and present, there appears to have
been little traction in correcting this imbalance.
This trend is potentially unsustainable for hospitals.
While earlier reports have often investigated EVAR costs
in comparison with open repair,8,11-16 ample evidence has
since accrued validating diminished EVAR-associated
morbidity and mortality.1-3 Furthermore, the supplemental
impact of patient driven demand for less invasive therapies
has obviated to some extent, the relevance of cost effective
analyses comparing the two procedures. Rather, EVAR has
rightly secured its foothold in contemporary aneurysm
practice, irrespective of cost. Therefore, the focus of this
analysis should be directed toward making EVAR-
associated costs and margins more neutral and, thus, palat-
able for sustainable healthcare systems.
The need for meaningful device cost reduction is
further highlighted by our ﬁnding that other major drivers
for procedure-associated cost, such as length of stay, at our
institution were already in the lowest quartile compared
with other academic centers, when benchmarked using
UHC 2012 publicly available data. The need for device
cost constraint is inevitably augmented by the current anal-
ysis demonstrating that mean device costs account for 52%
of the procedure cost, but assume 60% of the DRG
payment, highlighting the inequity between device cost
and current insufﬁcient DRG payment to adequately cover
these costs.
Alternatively, the need for DRG payment modiﬁcation
among Medicare beneﬁciaries to adequately cover high
cost devices seems unlikely in the setting of an overall
posture toward curbing Federal healthcare expenditures.
010
20
30
40
50
60
70
80
90
100
Vendor A Vendor B Vendor C Vendor D
% $18,607
$15,182 $16,636
$20,833
12% 9%
18%
54%
Fig 5. Vendor market share of total endovascular aneurysm repair (EVAR) practice with associated mean institutional
pricing. As shown (arrows), vendor D derived the largest market share, though it did not sell the lowest cost device,
whereas vendors A and B shared a smaller percentage of the market share, though their devices were less expensive.
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Fig 6. Projected vendor market shares reﬂecting shift in device utilization based on cost for the 44% of the total
endovascular aneurysm repair (EVAR) volume whereby devices can be used with clinical equipoise. As shown in the
ﬁgure (arrows), vendor A would increase market share from 12% to 51%, whereas vendor D would decrease its market
share from 54% to 30%.
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their 2002 analysis.4 Current expectations for increasing
DRG payments by the Centers for Medicare and Medicaid
Services would suggest at best modest increments by 2014
and are unlikely to sufﬁciently offset the negative margins
described herein.17
Interestingly, surgeons were largely unaware of the
pricing variation among devices and respective vendors,
in keeping with alternative healthcare economic reports.6
Historically, cost has not routinely factored into caseplanning paradigms for EVAR at our institution. We esti-
mate, based on anatomic review that roughly over 40% of
our EVAR practice could likely be treated interchangeably
by most commercially available devices with clinical equi-
poise. Accordingly, device cost awareness may serve to
foster shifts in market share to appropriately reﬂect compet-
itive pricing among stent graft vendors. We believe that
such changes in our practice pattern would have an imme-
diate savings of roughly $200,000 annually and serve to
offset our negative margin ﬁndings.
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revenues, and margins for EVAR are likely to ﬂuctuate
among institutions and regions across the country where
local practice and care delivery can vary. Furthermore,
this study only provides an isolated analysis of the EVAR
procedure itself with its associated margin. It does not
include other potential drivers for revenue associated with
EVAR care such as follow-up visits and computed tomog-
raphy scans. We opted to exclude this from our analysis, as
many large referral hospitals perform the EVAR procedure,
thus incurring the margins associated with the surgery but
not deriving the revenue from follow-up as these are often
performed at smaller referring hospitals, leading to the
phenomena of “destination care,” which may confound
costs analyses of care delivery. Nevertheless, we believe
the compelling procedure-associated margin ﬁndings at
our institution, may be prevalent across many hospitals
throughout the United States, for Medicare remunerated
cases. In addition, we did not include professional fees
and costs, as we believe they can vary substantially and
are less likely consistent across institutions pending indi-
vidual surgeon practice/hospital business models.
Furthermore, this analysis did not include DRG 237
remunerated EVAR, with major complications, where
procedure-associated costs may be even higher. To reach
a threshold for the higher paying DRG 237, a patient
must have a major complication or comorbidity (MCC).
For example, a history of congestive heart failure does
not qualify as an MCC. Rather, a patient must have acute
systolic heart failure. Due to this high threshold, qualifying
MCC patients are acutely ill and require substantial, incre-
mental resources to recover, thus signiﬁcantly impacting
associated costs and clouding the analyses. Thus, the
impact of maintaining a comprehensive EVAR program
may have a potentially ampliﬁed negative margin for hospi-
tals and health systems offering these services. This report
also did not include the minority of EVAR patients with
a private payer source, where rates of remuneration can
vary widely across institutions and regions, thus impacting
the ﬁnancial margin associated with the procedure.
CONCLUSIONS
In summary, DRG 238-remunerated EVAR was asso-
ciated with negative technical operating margins at our
institution. Stent grafts account for over 50% of the
procedure-associated technical costs and threefold more
than any other major nonimplant cost drivers. Device
cost did not predict vendor market share, demonstrated
by higher cost devices deriving larger EVAR market shares.
Moreover, surgeons were largely unaware of this cost
disparity and variation. Based on these ﬁndings and current
cost proﬁle, Medicare-remunerated EVAR is likely unsus-
tainable in the long term for hospitals that provide compre-
hensive EVAR care. In addition, surgeon awareness of
vendor price differentials may serve to both inform case
planning and better negotiate competitive device pricing.
Potential novel models for more cost neutral EVAR care
delivery predicated on cost transparency and potentialincreased DRG remuneration to offset margin losses are
needed for long-term sustainable healthcare systems.AUTHOR CONTRIBUTIONS
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at www.jvascsurg.org.DISCUSSIONDr Julie Ann Freischlag (Baltimore, Md). As you probably
are aware, we presented some results from UCLA about 13 years
ago that actually at that time showed that there was adequate fund-
ing for the grafts at that time even though they did contribute to
that high cost. And one of my greatest worries has been is when is
the day going to be that we cannot afford to do this? I guess that
day is today! Internationally, in many countries only those who can
afford to individually pay for high priced technology receive it.
My question to you is about the Veterans Affairs (VA). As you
know, we published the cost of the endovascular graft in the VA
setting and actually came out with the statement in our paper
that it actually was not more costly because the way accounting
is done in the VA system. All costs are spread like butter. So that
in the OVER trial, the endovascular grafts were not more expen-
sive than the open graft in that cost setting.
Do you think perhaps as we go ahead with health care reform
this could be the way costs of hospitalization are distributedd
spread across all patientsdlike butter?
Dr Stone. I think that is an interesting question. It is often
difﬁcult to extrapolate practice patterns in the VA system to the
university system. Clearly, at Dartmouth, where the whole
accountable care organization, ACO model, is being championed,
much scrutiny is being placed on individual procedure ﬁnances.
Certainly, the idea of cost sharing is an interesting one.
Currently at our institution we are even looking at care
delivery in a more granular fashion, a patient-focused economic
analysis, or PFEA. Therefore, even in a less magniﬁed view, if lesser
cost procedures were able to counteract some of the cost impact of
EVAR, I suspect from our hospital administration’s standpoint, an
unsustainable procedure-associated margin for EVAR is likely not
going to be a good practice pattern for long-term care.
Dr Freischlag. I think in the VA they did not ask anybody,
they just did it.
Dr W. Charles Sternbergh (New Orleans, La). I enjoyed
your paper very much and it is like kind of déjà vu all over again.
At the Society for Vascular Surgery meeting in 1999, I presented
data very similar to this. It was 3 months before the ﬁrst commer-
cial devices became available in the United States. And much to
everybody’s shock and surprise, we found the same thing. There
were higher costs for endovascular AAA repair, with the endograft
cost about 50% of the total hospital cost. I naively opined then that
surely these prices would come down as more competitors came
into the market; but endografts have gone from $8500 to
$9000 then, to about $15,000 to $18,000 now. So that has really
not happened.
I very much agree with your assessment that we in vascular
surgery must take a leadership role in raising awareness of these
hospital costs for endovascular aneurysm repair. Most vascular
specialists are unaware of these cost issues.
I have one question for you. Why did you exclude all of your
patients that were coded into DRG 237? Those are patients that, as
you suggested, have higher costs, but they also have higher
reimbursement.
Dr Stone. We chose to exclude those patients, with major
complications, billed using DRG 237, because we thought they
represented a different subset of EVAR treated patients. The
cost proﬁle and DRG remuneration, as you point out, is different.
We thought that our ﬁrst foray into this analysis would be to
look at the most simple EVARs, if you will, the so-calledapple-on-a-stick EVAR cases where other cost driving factors,
such as length of stay would not necessarily confound our analysis.
Moreover, when we looked at our DRG 237 billed volume,
we had roughly 12 patients over the study interval in that group
and, thus, chose to exclude them.
Since you made the point of graft prices and the lack of change
over time, I would add that we were somewhat surprised by these
ﬁndings. Moreover, in our own practice, we historically have not
factored device cost in case planning paradigms.
I would argue one potential reason why we have not seen
device cost reduction, across the country, is the obfuscation of
pricing by a myriad of reasons. As an example for instance, the
price we get at Dartmouth may not be the same price that you
are paying for the identical graft at your institution, which is alto-
gether different from the price that we pay for a different manufac-
turer and so forth. I think that this inherent lack of transparency
has led to this sustained practice pattern.
Dr Frank Sharp (Brick, NJ). You have partially answered my
question with your previous comments. Are you aware of any data
outside of the United States in terms of a similar analysis for the
cost for the devices? I think as vascular surgeons we need to
have these companies compete a little bit, and if these devices
are provided outside the United States for substantially less cost,
we should be aware of that.
Dr Stone. I agree completely. Yesterday I received the Wylie
Traveling Fellowship Award and that is exactly what our applica-
tion is about. We plan to examine this issue in Europe and look
at the cost of devices in different capitated systems for comparison.
But you are potentially correct that a lack of transparency in the
health care economics of our country may go a long way in subsi-
dizing expensive devices in other parts of the world.
Dr Krish Soundararajan (Wilmington, Del). This is a very
timely paper. I think it is naive for vascular surgeons to consider
treatment and therapies without understanding the cost factor.
However, I had a couple of concerns. I hope there is no Chief
Financial Ofﬁcer or Chief Executive Ofﬁcer in the audience here. I
would be concerned how they may hear your conclusion and be
adversely inﬂuenced on their support to develop programs that
embrace advanced technology.
I would like to suggest the way to look at this would be not to
include cost of endograft alone but to see how the hospital makes
revenue from the secondary aspects of an endograft. The patients
go through many computed tomography scans and utilize so many
other services and those could certainly very well make revenue for
the hospitals.
My ﬁrst question would be: When you analyzed the data, did
you include the modiﬁers for comorbidities? If you use the modi-
ﬁer in ICD coding, as per my understanding, the DRG payments
are likely to be better.
And the second question: If you think the cost of this is solely
driven by endograft, would it be fair to say there is very little we
can do as physicians?
Dr Stone. To your point about other aspects of EVAR that
generate revenue for health systems (ie, the CAT scans and so
forth), I think all politics is local. Where we practice medicine,
a so-called model of destination care exists. Speciﬁcally, many of
the EVARs that we perform are on patients who are seen and
imaged at smaller surrounding hospitals. And likewise those
follow-up computed tomography scans are often not performed
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do not derive any of the additional associated revenue you are
alluding to. I think this is a trend that may be pervasive for other
tertiary care referral centers around the country.
We did look at all of our EVARs. I do not think I could give
you an exact number of the number of our cases in our study
cohort who had modiﬁers attached to the DRG payment.
As to what we, physicians can do to address costs, I think that
is the big question. I think there are potentially many things we can
do at a microlevel, in our own respective environments. For
instance, if you look at our total EVAR practice, we estimate
that we can treat roughly 40% of our EVARs using any commer-
cially available device interchangeably with no impact to our
patients. Clearly, there is a cost implication of doing that and so
we can impact practice in that capacity. Ultimately, we need to
create an environment of cost transparency. If someone goes to
buy a car, one knows what the “Kelley Blue Book value” of that
car is when you are negotiating a price with your dealer. Thus
far, that does not exist in our profession. From a hospital and
surgeon standpoint, there is not a good reason why we cannot ulti-
mately try to impact that.
Dr Pathanjali Sharma (Reading, Pa). Is your data granular
enough to ﬁgure out what is the cost of the ancillary products
that we use during endografting, such as balloons, catheters,
sheaths, contralateral access, and extensions? Because that will
substantially add to the cost as I understand it.
Dr Stone. You raise a good point. We did look at that. And
again, that is part of the reason why we tried to start with
a more simple case complexity patient cohort, where a lot of
adjunctive supplies and so forth might confound cost analyses.
When examined, different catheters, closure devices for percuta-
neous access, wires and so forth, even when considered in aggre-
gate had a much smaller impact compared with the various stent
graft implantables.
Dr Michael Conte (San Francisco, Calif). David, I think your
paper is really important, particularly given that it is more than
a decade since Dr Sternbergh’s paper essentially showed similar
things. And today, although the technology for EVAR has pla-
teaued, we have not seen the reductions in costs or price that
would normally be associated with the market evolution of a tech-
nology in that way.
I can assure you we have the same issue at our institution.
And I just want to point out that you are looking at direct costs,but you did not even account for indirect costs such as keeping
the lights on and the mortars and bricks for the institution. For
every dollar in direct patient care costs at my hospital, it takes
60 cents to take out the garbage, keep the lights on, maintain
the physical plant, etc. And so, when they look at proﬁtability
and add the additional indirect costs, it looks even worse for an
EVAR case.
So I guess the point here is, is it not feasible that the vendor
costs for these devices could come down by 20% or 25% in the
environment where we now have ﬁve or six choices between
endografts for AAA, which would really make the procedures
almost revenue neutral?
My other question is: Did you look at patient factors such as
anatomy, age, or other comorbidities that could affect either the
revenue (ie, coding) or the cost side?
Dr Stone. To address the second point in your question ﬁrst,
we tried to anatomically derive a subset of patients, in whom we
thought anatomy was consistent, which we felt would impact
requisite devices and thus case-associated costs. We did not adjust
for age. There may be some small disparities within that group in
terms of comorbidity proﬁle which we did not account for. But
from a cost and anatomy standpoint, we thought this study group
would be anatomically more homogeneous.
To your point about being more revenue neutral, I would
agree, but add that our operating margins did include allocated
costs and, thus, some institutional overhead costs. I would agree,
however, that it is not unfeasible to aim for a 20% cost reduction
to make this a more revenue neutral procedure.
I know our orthopedic colleagues have been successful in
negotiating substantial reductions in price for their devices,
moving to fewer vendors for joint replacement. Obviously, for
reasons that are not equivalent, we are not willing to, at this point,
go to an exclusive provider for numerous reasons.
Dr Fred Weaver (Los Angeles, Calif). Have you done, and
maybe it is difﬁcult in this endovascular era, but have you done
a similar kind of analysis of open repair at Dartmouth?
Dr Stone. The answer is we have not. The main reason why
we did not was because we believe that cost-effective analyses for
EVAR have already been performed. Furthermore, and at this
point, we believe irrespective of the cost proﬁle of EVAR, EVAR
is clearly here and here to stay in our respective practices. There-
fore, it is not so much a matter of whether open is more cost-palat-
able but whether we can make EVAR more cost-effective.
Supplementary Table (online only). Exclusion criteria
No. %
Total EVARs performed 127 100
Complexity and anatomy exclusion 71 56
Multiple manufacturer exclusion 9 7
Non-Medicare exclusion 13 10
Non-DRG 238 exclusion 15 12
DRG, Diagnosis-related group; EVAR, endovascular aneurysm repair.
The net cohort of 49 patients reﬂects the combination of all inclusion/
exclusion percentages from the total sample. Several cases had more than
one exclusion criteria.
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